IDEAYA Biosciences, Inc. (IDYA) has been beaten down lately with too much selling pressure. While the stock has lost 8.6% ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

In a challenging year for biotech firms, Ideaya Biosciences Inc . (NASDAQ:IDYA) stock has reached a 52-week low, touching down at $21.02. According to InvestingPro data, the company maintains strong ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of ...

Oppenheimer lowered the firm’s price target on Ideaya Biosciences (IDYA) to $40 from $53 and keeps an Outperform rating on the shares after the ...

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

Reports Q4 revenue $7M, consensus $4.31M. The net loss for the three months ended December 31, 2024, was $130.3M compared to the net loss of ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced financial results for the quarter and full ...

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, Monday announced the appointment of Joshua Bleharski as chief financial officer. Before joining IDEAYA ...

IDEAYA Biosciences named Joshua Bleharski as its top finance chief, effective in early May.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a biotechnology company specializing in targeted therapies for cancer, is positioning itself for a transformative year in 2025. Currently trading near its ...